Evidence map›Paper›PMID 32865454›Full record

ArticleJournal of aerosol medicine and pulmonary drug delivery2021

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.

Richard Allan, Kelly Canham, Roisin Wallace, Dave Singh, Jon Ward, Andrew Cooper, Claire Newcomb

Open access · hybridAbstract read
In one paragraph

Article in Journal of aerosol medicine and pulmonary drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.Journal of aerosol medicine and pulmonary drug delivery · 2020
    Trial
  2. Review
  3. Journal of aerosol medicine and pulmonary drug delivery · 2022
    Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Richard AllanMylan, Inc., Sandwich, Kent, United Kingdom.
Kelly CanhamMylan, Inc., Sandwich, Kent, United Kingdom.
Roisin WallaceMylan Global Device Development, Dublin, Ireland.
Dave SinghMedicines Evaluation Unit, The University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Jon WardMylan, Inc., Sandwich, Kent, United Kingdom.
Andrew CooperMylan, Inc., Sandwich, Kent, United Kingdom.
Claire NewcombMylan, Inc., Sandwich, Kent, United Kingdom.
Manchester University NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dry Powder InhalersUser-Computer InterfaceAdministration, InhalationAdultAgedAndrostadienesBronchodilator AgentsChildFluticasoneHumansPowdersSalmeterol XinafoateAndrostadienesBronchodilator AgentsFluticasonePowdersSalmeterol XinafoateasthmaCOPDdevice orientationfluticasone propionate/salmeterol

Identifiers

PMID32865454
PMCPMC8060712
OpenAlexW3082062420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.